![Blaise Lippa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Blaise Lippa
Director Técnico/Científico/I+D en
MORC HOLD
.
Perfil
Blaise Lippa is currently the Chief Scientific Officer at Morphic Therapeutic, Inc. since 2015 and at Morphic Holding, Inc. since 2022.
Previously, Blaise worked as the Senior Director-Medicinal Chemistry at Cubist Pharmaceuticals LLC.
Blaise holds a doctorate degree from Stanford University and an undergraduate degree from the University of Michigan.
Cargos activos de Blaise Lippa
| Empresas | Cargo | Inicio |
|---|---|---|
| MORC HOLD | Director Técnico/Científico/I+D | 12/05/2022 |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Director Técnico/Científico/I+D | 01/06/2015 |
Antiguos cargos conocidos de Blaise Lippa.
| Empresas | Cargo | Fin |
|---|---|---|
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Formación de Blaise Lippa.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
8
Relaciones de 1er grado
5
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Morphic Holding, Inc.
 Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
- Bolsa de valores
- Insiders
- Blaise Lippa
